With respect to target validation in new and/or established AD models, we confirmed that inhibitors of the protein expressed by AMP AD–nominated target EPHX2 reduce tau phosphorylation in AD‐relevant neurons. This evidence concerns the gene MAPT and Alzheimer disease.